CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 547 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mevociclib
CAS:Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.Fórmula:C31H35ClN8O2Pureza:98.02% - 98.02%Cor e Forma:SolidPeso molecular:587.11CDK7-IN-14
CAS:CDK7-IN-14 (compound 3) is a pyrimidine-derived CDK7 inhibitor applicable for studying cancers associated with transcriptional dysregulation.Fórmula:C22H24F3N6OPPureza:99.24% - 99.48%Cor e Forma:SolidPeso molecular:476.43Riviciclib
CAS:Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.Fórmula:C21H20ClNO5Pureza:98%Cor e Forma:SolidPeso molecular:401.84ML 315 hydrochloride
CAS:ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].
Fórmula:C18H14Cl3N3O2Cor e Forma:SolidPeso molecular:410.682Nε-(1-Carboxyethyl)-L-lysine
CAS:Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.Fórmula:C9H18N2O4Cor e Forma:SolidPeso molecular:218.25CDK7-IN-22
CAS:CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].Fórmula:C22H25F3N6Pureza:98%Cor e Forma:SolidPeso molecular:430.47CCT-251921
CAS:CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).Fórmula:C21H23ClN6OPureza:99.07%Cor e Forma:SolidPeso molecular:410.9Ref: TM-T14901
1mg90,00€1mL*10mM (DMSO)192,00€5mg210,00€10mg308,00€25mg520,00€50mg745,00€100mg1.018,00€CDK7-IN-25
CAS:CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].Fórmula:C33H32N6O3Pureza:98%Cor e Forma:SolidPeso molecular:560.65IIIM-290
CAS:IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).Fórmula:C23H21Cl2NO5Pureza:98%Cor e Forma:SolidPeso molecular:462.32Cdc7-IN-7
CAS:Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
Fórmula:C21H22N4O5Pureza:98.78%Cor e Forma:SolidPeso molecular:410.42Cdk4 Inhibitor
CAS:PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.Fórmula:C20H10BrN3O2Cor e Forma:SolidPeso molecular:404.2Cdk1/2 Inhibitor III
CAS:Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.Fórmula:C15H13F2N7O2S2Pureza:99.92%Cor e Forma:SolidPeso molecular:425.44AZD4573
CAS:AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Cor e Forma:SolidPeso molecular:429.94XY028-140
CAS:XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.Fórmula:C39H40N10O7Pureza:98.59%Cor e Forma:SolidPeso molecular:760.8Debio-0123
CAS:Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.Fórmula:C26H28Cl2N6OPureza:99.93%Cor e Forma:SolidPeso molecular:511.45CF53
CAS:CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.Fórmula:C24H25N7O2Pureza:99.72%Cor e Forma:SolidPeso molecular:443.5Ref: TM-T10773
1mg92,00€5mg200,00€1mL*10mM (DMSO)215,00€10mg299,00€25mg484,00€50mg658,00€100mg892,00€(R)-Simurosertib
CAS:(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.Fórmula:C17H19N5OSPureza:99.89%Cor e Forma:SolidPeso molecular:341.43CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Fórmula:C20H25N3O4Pureza:98%Cor e Forma:SolidPeso molecular:371.43CDK2-IN-18
CAS:CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].Fórmula:C21H23N7O2SCor e Forma:SolidPeso molecular:437.52CDK2 degrader 6
CAS:CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Fórmula:C23H22F5N5O3Cor e Forma:SolidPeso molecular:511.44Tizolemide
CAS:Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Fórmula:C11H14ClN3O3S2Cor e Forma:SolidPeso molecular:335.83INX-315
CAS:INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Fórmula:C19H21N7O3SPureza:99.88%Cor e Forma:SolidPeso molecular:427.48CDDD11-8
CAS:CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Fórmula:C24H26N6Cor e Forma:SolidPeso molecular:398.50Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Fórmula:C37H52N6O5Cor e Forma:SolidPeso molecular:660.85SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Fórmula:C19H15F3N6O2Cor e Forma:SolidPeso molecular:416.36CDK8-IN-5
CAS:CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Fórmula:C26H22N2O4Cor e Forma:SolidPeso molecular:426.46PROTAC CDK12/13 Degrader-1
PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.Cor e Forma:SolidCDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Fórmula:C19H16ClF3N4O2Cor e Forma:SolidPeso molecular:424.8CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Fórmula:C18H20N4Cor e Forma:SolidPeso molecular:292.38CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Fórmula:C19H15F3N4O2Pureza:99.74%Cor e Forma:SolidPeso molecular:388.34Ref: TM-T61742
1mg54,00€5mg114,00€1mL*10mM (DMSO)126,00€10mg178,00€25mg409,00€50mg708,00€100mg982,00€RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Fórmula:C29H37Cl2N7O4Cor e Forma:SolidPeso molecular:618.55Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK7-IN-17
CAS:CDK7-IN-17 (compound 11) is a pyrimidine-derived CDK7 inhibitor for studying transcription-disrupted cancers.Fórmula:C24H26F3N6OPPureza:99.60%Cor e Forma:SolidPeso molecular:502.47CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83CDK9-IN-13
CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.Fórmula:C27H35N5O2Cor e Forma:SolidPeso molecular:461.6CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Fórmula:C28H25ClF3N5O2Cor e Forma:SolidPeso molecular:555.98CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Fórmula:C20H18N4O4Cor e Forma:SolidPeso molecular:378.38CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699CDK8-IN-9
CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.Cor e Forma:SolidYL-1-9
CAS:YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].Fórmula:C22H23F3N2O3Cor e Forma:SolidPeso molecular:420.425CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Fórmula:C21H20F3N7OPureza:98%Cor e Forma:SolidPeso molecular:443.42GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347
